Fate Therapeutics appoints Dr. Neely Mozaffarian to Board, expanding to 10 members

FATE THERAPEUTICS INC

Dr. Mozaffarian appointed effective July 29, 2024, as Class II director and member of NCG and Science & Technology committees.
Board increased from 9 to 10 directors; Mozaffarian fills newly created vacancy.
Received option to purchase 80,000 shares at July 29 closing price, vesting monthly over 36 months.
Mozaffarian is CMO at Atomwise with over 20 years immunology/autoimmunity R&D leadership.
Appointment adds expertise in autoimmune disease and cell therapy development.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Neelufar Mozaffarian

Class II director

FATE · FATE THERAPEUTICS INC

Effective: 2024-07-29
Filed: July 31, 2024, 7:59 PM ET

On July 29, 2024, the Board, following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Neelufar Mozaffarian, M.D., Ph.D., FACR, to the Board, to serve as a Class II director and member of the NCG Committee and the Science and Technology Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neelufar Mozaffarian was appointed as Class II director at FATE THERAPEUTICS INC.

Action: appointed
Role: Class II director

Exact text from the filing

On July 29, 2024, the Board, following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Neelufar Mozaffarian, M.D., Ph.D., FACR, to the Board, to serve as a Class II director and member of the NCG Committee and the Science and Technology Committee of the Board.

View on SEC.gov

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-24-189911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.